Six months after Amgen and AstraZeneca reported promising results for Tezspire (tezepelumab) as a potential treatment for chronic obstructive pulmonary disorder (COPD), the companies are touting ...
TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo Positive high-level results from the ...
Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgen’s ...
AstraZeneca and Amgen have released topline data from a Phase III trial of its inflammatory therapy, Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
WILMINGTON, Del., November 08, 2024--(BUSINESS WIRE)--Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps ...
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
The trial demonstrated patients treated with TEZSPIRE® (tezepelumab-ekko) had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal ...
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
The trial demonstrated patients treated with TEZSPIRE® (tezepelumab-ekko) had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal ...
The safety profile and tolerability of Tezspire in this trial were consistent with the known profile of the medicine. Tezspire is currently approved for severe asthma in the US, EU, Japan ...
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
WAYPOINT was a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of TEZSPIRE administered subcutaneously in adults with severe CRSwNP. Participants in the trial ...
AstraZeneca (AZ) and Amgen have shared positive results from a late-stage study of Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The phase 3 WAYPOINT trial ...
AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Tezspire has shown promising results in the Phase III WAYPOINT trial, demonstrating significant reductions in nasal polyp size and ...
Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgen’s TEZSPIRE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback